New vaccine for hepatitis C virus

Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

HCV is spread through blood-to-blood contact and causes liver inflammation and . It affects about 284,000 and 212,000 are living with chronic HCV.

The research in collaboration with Oxford University and funded by the McCusker Foundation, is using a new approach to develop the vaccine, which aims to protect against the majority of circulating HCV strains.

Researcher Michaela Lucas said: “Previous attempts to create a vaccine have been limited because like HIV, escapes our immune system by rapid change of its genome and shape.

“Our project is using genetics to identify these escape patterns so we can create vaccines that take this ability of the virus to change into account. That should mean a higher chance of success.”

Dr. Lucas said if successful, the vaccine could halt the infection cycle by protecting people at risk from initial infection and re-infection.

virus infection is a major global health problem and despite public health efforts in Australia to prevent HCV infection, it has become the most common blood–borne infection,” she said.

“There is currently no vaccine for the prevention of HCV and previous HCV infection does generally not protect from re-infection. Furthermore, available treatment is not accessible to all, is expensive and can have life-threatening complications.

“Even if treatment and newer treatment strategies are successful and eradicate the virus within an individual, it will not prevent re-infection, which is common in high-risk exposure groups.  A vaccine against HCV would provide a mechanism to stop the continuation of the infection cycle.”

add to favorites email to friend print save as pdf

Related Stories

Early treatment is key to combating hepatitis C virus

Aug 08, 2008

Canadian researchers have shown that patients who receive early treatment for Hepatitis C virus (HCV) within the first months following an infection, develop a rapid poly-functional immune response against HCV similar to ...

Possible hepatitis C vaccine

Sep 05, 2007

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort ...

Improved culture system for hepatitis C virus infection

Jul 16, 2008

A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment ...

Scientists Model Hepatitis C Virus

May 25, 2007

One of the most common life-threatening viral infections in the United States today is hepatitis C virus (HCV). The standard treatment is successful in only about 50 percent of treated HCV chronic patients, with no effective ...

Recommended for you

Determine patient preferences by means of conjoint analysis

9 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments